← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #332 OF 1,000 MOST-CITED

Lack of or inadequate organizational structure

FDA cited this observation 83 times across 81 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices83
BY FISCAL YEAR
FY20261
FY202510
FY20248
FY20236
FY20223
FY20212
FY20205
FY201910
FY201814
FY201714
FY201610

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 2.2× the rate of the average FDA-cited firm (17.3% vs 7.7%), across 81 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

The organizational structure has not been adequately established and maintained to ensure that devices are designed and produced in accordance with 21 CFR 820.

Longhorn Vaccines And Diagnostics LLC · Bethesda, Maryland · Devices · 2025-10-30

The organizational structure has not been established and maintained to ensure that devices are in accordance with 21 CFR 820.

Sparsha Pharma Usa Inc · Oceanside, California · Devices · 2025-09-04

The organizational structure has not been adequately established and maintained to ensure that devices are produced in accordance with 21 CFR 820.

Pharmacaribe, LLC · Naples, Florida · Devices · 2025-08-20

The organizational structure has not been adequately established and maintained to ensure that devices are produced in accordance with 21 CFR 820.

Folsom Metal Products, Inc. · Pelham, Alabama · Devices · 2025-08-01

The organizational structure has not been adequately established and maintained to ensure that devices are designed and produced in accordance with 21 CFR 820.

Contec Medical Systems Co., Ltd. · Qinhuangdao · Devices · 2025-06-12

The organizational structure has not been adequately established and maintained to ensure that devices are designed and produced in accordance with 21 CFR 820.

Triumph Pharmaceuticals Inc. · Saint Louis, Missouri · Devices · 2025-04-29

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →